InvestorsHub Logo
Followers 1
Posts 27
Boards Moderated 0
Alias Born 02/06/2013

Re: None

Wednesday, 10/16/2013 5:53:22 PM

Wednesday, October 16, 2013 5:53:22 PM

Post# of 425377
Where to from here?

I'll be curious to hear what the company has to say tonight but I don't think they have a contingency plan ready to go other than to move forward with Marine, pray the FDA rejects the AdComm's Anchor recommendation (can't see this happening after a 9-2 vote) and maybe hope that a decent buyout offer presents itself. We can all forget the SR-fueled $28-32 buyout dreams. Personally I would be happy with $10 in light of the long wait/dilution we would have to endure while hoping the Reduce-It results are positive (which I anticipate).

As far as a buyout is concerned, perhaps I'm a bit of a conspiracy theorist but I'm still scratching my head at how the AdComm went down today. Here you have a drug that has no harmful side effects, is proven to reduce TGs and will in all likelihood be shown to help with CVD (based on JELIS) not to mention all the other potential benefits yet it is overwhelmingly rejected?? The only winner I can see here is BP that can now throw a low ball offer at the company and say take it or leave it.

I've been long a few years here but never imagined this would happen. The only thing I know I won't do is sell at anything under $10. I'd rather hold this stock for the next ten years if I have to than do that.

GLTAL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News